GlassScriptPhysician profile
Daniel H Sterman
NPI 1851325922
$27,004.57
in general payments reported to CMS, 2019-2025
12 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,818 · 2020: $14K · 2021: $1,001 · 2022: $145 · 2023: $337 · 2024: $3,562 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,116 · Consulting Fee: $1,000 · Travel and Lodging: $705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,116.30 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $704.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gyrus Acmi, INC. | $11,660.00 | 2020 | |
| Spiration, INC. | $6,498.12 | 2019-2020 | |
| Intuitive Surgical, INC. | $3,941.37 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,083.57 | 2020-2025 | Tagrisso |
| Galvanize Therapeutics, INC | $1,514.57 | 2023-2025 | Aliya System |
| Boehringer Ingelheim International Gmbh | $969.50 | 2021 | |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.00 | 2022 | |
| Novocure INC. | $31.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.94 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sterman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.